Nath Bio-Genes (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve unaudited financial results for the quarter and half year ended 30th September 2026

07th November 2026 The Manager-Listing The Manager- Listing BSE Limited National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra-Kurla Complex Dalal Street, Bandra (E) Mumbai-400001 Mumbai-400051 BSE Code-537291 NSE Code-NATHBIOGEN Sub: Intimation of Board Meeting to consider Unaudited Financial Results of the Company for the quarter and half year ended 30th September 2026. Ref: Regulation 29 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015. Dear Sir/Madam, Pursuant to Regulation 29 and 33 of the Listing Regulations 2015, Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Saturday, 14th November 2026 to approve the following. 1. To consider, approve and take on record Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended 30th September 2026. 2. Any other business with the permission of board. The Company has already closed its “Trading Window” under the Code of Conduct for prevention of Insider Trading from 30th September 2026 and it will re-open on 17th November 2026. You are requested to take note of the above. Thanking You. Yours faithfully, For Nath Bio-Genes (India) Limited, Amol Gupta Chief Financial Officer